Annidis Corporation Announces Partnership with Retinal Consultants of Arizona

OTTAWA, Nov. 19, 2014 /CNW/ - Annidis Corporation (TSX Venture: RHA) ("Annidis" or the "Company") today announced that Retinal Consultants of Arizona (RCA) has added Annidis RHA instrument into its patient-based offering across the state of Arizona. RCA is one of America's leading Retinal and Vitreous clinical research and patient treatment facilities. This partnership will allow RCA to continue its leadership in patient care by offering the best available technologies for examination and diagnosis of retinal eye diseases.

"Annidis RHA is the most advanced retinal imaging system based on Multi-Spectral Imaging technology. This new technology allows us to detect changes at the layers of the retina and choroid better than anything before," said Dr. Pravin Dugel, Managing Partner, Retinal Consultants of Arizona. "Integrating this level of medical imaging technology into our daily practice of patient care gives us the ability to detect disease at the earliest stages and enables us to start treating diseases before a patient is at risk of losing their sight. Additionally, this level of imaging enables us to better assess the effects of drugs and laser treatment in many aging Arizonians suffering from diseases such as macular degeneration and vitreo-retinal diseases, potentially leading to better outcomes." 

"Throughout the US, the physicians at Retinal Consultants of Arizona are well-known as leaders in the treatment and clinical research of retina and vitreous related diseases," said Nick Ribaric, President, Annidis Corporation. "It is our honor to work with industry-leading medical professionals and to have our RHA instruments available for the purpose of advanced patient care and diagnosis of disease affecting so many people. Our technology is designed to help physicians provide safer, accurate and real-time diagnosis of complex retina diseases in order to save sight and prevent blindness."

The advantages of Annidis RHA include maximizing patient examinations, while reducing invasive tests and procedures to yield the same or better diagnostic quality. The RHA™ instrument is a multi-spectral imaging digital ophthalmoscope that captures high-resolution image data through the retinal and sub retinal layers.

Multi-spectral imaging extends the analysis eye care professionals use to distinguish between ocular structures. It both expands the examination wavelength range from green to invisible near infrared light and generates the probe wavelengths to separate specific spectral regions for enhanced visibility and discrimination. The combination of the images and extracted data points provides an enhanced view of the eye.

About Annidis Corporation

Annidis (TSX-V: RHA) has developed and is marketing a new imaging platform technology based on Multi-Spectral Imaging (MSI). This new technology is opening a new frontier in disease identification and its management. The Annidis MSI technology allows eye-care professionals to view non-invasively the deepest areas of the eye aiding eye care professionals in the early identification and treatment of debilitating eye diseases. The Company's existing RHA 2020-U Gold, used by eye care professionals as a broad based tool for detecting early-onset of eye related diseases such as Dry AMD, has a potential market of over 20,000 clinics in North America. The RHA Platinum MD will further strengthen the value proposition allowing doctors to visualize choroidal and retinal vasculature non-invasively. The RHA Platinum MD has global market potential of more than 100,000 Ophthalmologists

About Retinal Consultants of Arizona

Retinal Consultants of Arizona (RCA) was established in 1980 in central Phoenix. Since then, RCA has grown to include 24 offices throughout Arizona, providing improved access to the highest quality medical eye care. RCA also manages the country's leading independent clinical research & trials facility, Retinal Research Institute, where RCA physicians contribute to the advancement of new therapies by participating in clinical research studies. RCA helps more than 250,000 Arizona patients annually to maintain their sight. 

Retinal Consultants of Arizona is proud to have become Arizona's largest and most experienced ophthalmology practice and nationally recognized clinical research facility focused specifically on the diagnosis and management of the retina and vitreous. In many instances, RCA is the only retina group in Arizona to offer participation in specific research trials. We accept new patients every day, and urgent or emergency referrals are seen the same day www.retinalconsultantsaz.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Annidis Corporation

Gerald Slemko, Chief Executive Officer, Annidis Corporation, [phone] ext. 239, [email protected]; Babak Pedram, Investor Relations, Virtus Advisory Group Inc., 416-995-8651, [email protected]